Abstract
The concept of mild cognitive impairment (MCI) was first introduced for the purpose of identifying individuals in an intermediate state between no cognitive impairment and Alzheimer’s disease (AD). Recently, the heterogeneity of MCI has attracted attention as it has become clear that other diseases, such as cerebrovascular disease and Parkinson disease can also cause mild cognitive deficits, prompting a redefinition of MCI. Heterogeneity of MCI has been confirmed by neuropathological examinations. Most MCI patients not only possess amyloid plaques and neurofibrillary tau tangles, but also cerebral vascular pathology such as arteriosclerosis and cerebral amyloid angiopathy (CAA). CAA induces cerebral infarcts or hemorrhage of varying size and type, attributing to further cognitive impairment. Sporadic AD and CAA has been suggested to be the consequence of Aβ elimination failure, mainly caused by disturbance of the perivascular drainage system. Since severe CAA is an independent risk factor for dementia, facilitation of Aβ clearance has been suggested as a potential treatment of AD and MCI. Many epidemiological studies have shown that vascular risk factors increase incidence of MCI and its progression to AD. Accordingly, control of such factors has been shown to reduce risk of conversion to AD and ameliorate cognitive impairment in AD patients. Neurovascular approaches may therefore hold promise for the treatment of dementia in an era of preventive neurology.
Keywords: Alzheimer’s disease, cerebral amyloid angiopathy, cerebrovascular disease, cilostazol, diagnosis, microinfarcts, mild cognitive impairment, neurocognitive disorder.
Current Alzheimer Research
Title:Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Volume: 12 Issue: 6
Author(s): Satoshi Saito, Yumi Yamamoto and Masafumi Ihara
Affiliation:
Keywords: Alzheimer’s disease, cerebral amyloid angiopathy, cerebrovascular disease, cilostazol, diagnosis, microinfarcts, mild cognitive impairment, neurocognitive disorder.
Abstract: The concept of mild cognitive impairment (MCI) was first introduced for the purpose of identifying individuals in an intermediate state between no cognitive impairment and Alzheimer’s disease (AD). Recently, the heterogeneity of MCI has attracted attention as it has become clear that other diseases, such as cerebrovascular disease and Parkinson disease can also cause mild cognitive deficits, prompting a redefinition of MCI. Heterogeneity of MCI has been confirmed by neuropathological examinations. Most MCI patients not only possess amyloid plaques and neurofibrillary tau tangles, but also cerebral vascular pathology such as arteriosclerosis and cerebral amyloid angiopathy (CAA). CAA induces cerebral infarcts or hemorrhage of varying size and type, attributing to further cognitive impairment. Sporadic AD and CAA has been suggested to be the consequence of Aβ elimination failure, mainly caused by disturbance of the perivascular drainage system. Since severe CAA is an independent risk factor for dementia, facilitation of Aβ clearance has been suggested as a potential treatment of AD and MCI. Many epidemiological studies have shown that vascular risk factors increase incidence of MCI and its progression to AD. Accordingly, control of such factors has been shown to reduce risk of conversion to AD and ameliorate cognitive impairment in AD patients. Neurovascular approaches may therefore hold promise for the treatment of dementia in an era of preventive neurology.
Export Options
About this article
Cite this article as:
Saito Satoshi, Yamamoto Yumi and Ihara Masafumi, Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction, Current Alzheimer Research 2015; 12 (6) . https://dx.doi.org/10.2174/1567205012666150530202508
DOI https://dx.doi.org/10.2174/1567205012666150530202508 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Annurca Apple Fruit, a Southern Italy Cultivar, on Lipid Metabolism in Wistar Rats
Current Nutrition & Food Science Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine The Use of SIFT-MS to Investigate Headspace Aldehydes as Markers of Lipid Peroxidation
Current Analytical Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Post-traumatic Stress Disorder in Heart Failure Patients: A Test of the Cardiac Disease-induced PTSD Hypothesis
Current Psychiatry Research and Reviews Nutrition Communication in General Practice
Current Nutrition & Food Science Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Palladium-Catalyzed Oxyarylation, Azaarylation and α-Arylation Reactions in the Synthesis of Bioactive Isoflavonoid Analogues
Current Organic Synthesis Exercise and Ischemic Preconditioning
Current Cardiology Reviews Bioresorbable Scaffolds for Atheroregression: Understanding of Transient Scaffolding
Current Cardiology Reviews Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Recent Trends in the Design, Synthesis and Biological Exploration of β-Lactams
Current Medicinal Chemistry Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Current Drug Delivery Mexiletine Metabolites: A Review
Current Medicinal Chemistry